Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade

Basit Öğe Kaydı
dc.authoridKim, Stefano/0000-0003-2851-7119
dc.authorwosidMiksad, Rebecca Anne/GPF-9176-2022
dc.contributor.authorKelley, Robin Kate
dc.contributor.authorMiksad, Rebecca
dc.contributor.authorCicin, Irfan
dc.contributor.authorChen, YenHsun
dc.contributor.authorKlumpen, Heinz-Josef
dc.contributor.authorKim, Stefano
dc.contributor.authorLin, Zhong-Zhe
dc.date.accessioned2024-06-12T11:17:49Z
dc.date.available2024-06-12T11:17:49Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground Albumin-bilirubin (ALBI) grade is an objective measure of liver function for patients with hepatocellular carcinoma (HCC). The tyrosine kinase inhibitor cabozantinib is approved for patients with advanced HCC who have received prior sorafenib based on the phase 3 CELESTIAL trial (NCT01908426). Cabozantinib improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated HCC. Methods Patients were randomised 2:1 to receive cabozantinib 60 mg or placebo orally every day. Clinical outcomes in patients with ALBI grade 1 or 2 at baseline were evaluated in CELESTIAL. ALBI scores were retrospectively calculated based on baseline serum albumin and total bilirubin, with an ALBI grade of 1 defined as <= -2.60 score and a grade of 2 as a score of > -2.60 to <= -1.39. Results Cabozantinib improved OS and PFS versus placebo in both ALBI grade 1 (hazard ratio [HR] [95% CI]: 0.63 [0.46-0.86] and 0.42 [0.32-0.56]) and ALBI grade 2 (HR [95% CI]: 0.84 [0.66-1.06] and 0.46 [0.37-0.58]) subgroups. Adverse events were consistent with those in the overall population. Rates of grade 3/4 adverse events associated with hepatic decompensation were generally low and were more common among patients in the ALBI grade 2 subgroup. Discussion These results provide initial support of cabozantinib in patients with advanced HCC irrespective of ALBI grade 1 or 2.en_US
dc.description.sponsorshipExelixis, Inc.en_US
dc.description.sponsorshipThis study was supported by Exelixis, Inc.en_US
dc.identifier.doi10.1038/s41416-021-01532-5
dc.identifier.endpage575en_US
dc.identifier.issn0007-0920
dc.identifier.issn1532-1827
dc.identifier.issue4en_US
dc.identifier.pmid34621044en_US
dc.identifier.scopus2-s2.0-85116817676en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage569en_US
dc.identifier.urihttps://doi.org/10.1038/s41416-021-01532-5
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24860
dc.identifier.volume126en_US
dc.identifier.wosWOS:000704938600003en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.ispartofBritish Journal Of Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChild-Pughen_US
dc.subjectLiver-Functionen_US
dc.subjectSorafeniben_US
dc.subjectHccen_US
dc.titleEfficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin gradeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu